Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients
News Saturday, July 5th, 2014Wiley: 12 JUN 2014
-
Conflict of interest: Dr. Amarenco has received research funding from Pfizer, AstraZeneca, Merck, Sanofi-Aventis, and BMS; speaker fees from Pfizer, Sanofi-Aventis, Bayer, Boehringer-Ingelheim, AstraZeneca, and Otsuka Pharmaceutical; and honoraria from Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Merck, Kowa, Lundbeck, Boston Scientific, Edwards, Bayer, and Boehringer-Ingelheim.
-
Dr. Abboud has no conflicts of interest to disclose.
-
J. Labreuche has no conflicts of interest to disclose.
-
Dr. Arauz has received speaker fees from Boehringer-Ingelheim and Pfizer.
-
Dr. Bryer has received research funding from Sanofi-Aventis, Boehringer-Ingelheim, Novartis, MSD, Solvay Pharmaceuticals, UCB, and GlaxoSmithKline and consulting/speaking fees from Boehringer-Ingelheim, Bayer, and Sanofi-Aventis.
-
Dr. Lavados has received research funding from the George Institute for Global Health, Lundbeck, Boehringer-Ingelheim, and Bristol-Myers Squibb and sits on the advisory boards of Bristol-Myers Squibb and Sanofi-Aventis.
-
Dr. Massaro has received speaker fees from Sanofi-Aventis, Boehringer-Ingelheim, Bayer, Ferrer Group, and Novartis.
-
Dr. Munoz Collazos has received research funding from Sanofi-Aventis, PROCAPS, and Biotoscana; speaker fees from Bayer Colombiana, Boehringer-Ingelheim, and Ferrer Group; honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim; and travel and educational funding from Ferrer Group, Lundkeck, Sanofi-Aventis, Boehringer-Ingelheim, Tecnofarma, Bayer Colombiana, and Biotoscana. Read More